Seed financed by Sofinnova Partners, Bionyra was co-founded by Sofinnova Partners and Frédéric Marrache, MD, PhD, MBA. Prior to joining Bionyra, Frédéric served as Vice President for Clinical Development in the Immunology and Inflammation Therapeutic Area at Sanofi where he led a portfolio of drug development programs focused on immune-mediated diseases. The company is committed to overcoming the limitations of existing therapies by delivering patient-optimized treatments with greater efficacy and improved convenience, offering better and longer-lasting outcomes.
Severe immune-mediated inflammatory diseases impose a constant toll as patients live with a high daily burden of pain, fatigue and uncertainty, structuring their lives around flares, hospital visits and treatment setbacks. Current therapies often target single nodes of complex immune networks, limiting depth and durability of response. Many patients cycle through multiple therapies without achieving sustained relief or meaningful improvements in quality of life, highlighting the need for better therapeutic options that can improve clinical outcomes.
Bionyra is launching with a broad pipeline of clinical and near-clinical, next-generation anti-inflammatory therapies designed to deliver first- and best-in-class treatments by combining targeted biology with optimized pharmacokinetics, including:
BYN-002
A leading TL1A monoclonal antibody with half-life extension (HLE) technology with best-in-class potential in IBD and other TL1A-relevant indications. A Phase 1 study in healthy subjects is fully enrolled. TL1A is a cytokine that drives chronic inflammation, tissue damage and fibrosis in immune-driven diseases, including IBD and other immune-mediated conditions. BYN-002 was designed to minimize dosing frequency and offers a significant opportunity to impact patient outcomes.
BYN-003
A first and best-in-class TL1A*IL-23p19 bispecific monoclonal antibody with HLE technology with a Phase 1 study now underway. Targeting both TL1A and IL-23 through a bispecific antibody (a single molecule that targets both signals at the same time) can offer a more efficient way to dial down multiple drivers of disease.
BYN-001
A first and best-in-class IL-25 monoclonal antibody with half-life extension (HLE) technology in IND-stage for atopic dermatitis and Type 2 inflammation. IL-25 is a key pathogenic alarmin that drives Type 2 inflammation beyond downstream effector cytokines like IL-4 and IL-13. Blocking IL-25 has been shown to reduce inflammation and helps restore immune balance.
The company licensed BYN-002 and BYN-003 from TrueLab Biopharmaceutical and BYN-001 from NovaRock Biotherapeutics and holds exclusive global rights outside of Greater China. In addition, Bionyra is progressing additional innovative preclinical assets, including some from TrueLab.
Bionyra’s oversubscribed Series A financing was co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures also participated in this inaugural funding. 
